Analysts Offer Predictions for Exact Sciences Q1 Earnings

Exact Sciences Co. (NASDAQ:EXAS - Free Report) - Leerink Partnrs upped their Q1 2025 EPS estimates for shares of Exact Sciences in a research note issued to investors on Thursday, February 20th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.10). The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q2 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.26 EPS and Q4 2026 earnings at $0.34 EPS.

A number of other brokerages have also weighed in on EXAS. Craig Hallum cut their target price on shares of Exact Sciences from $82.00 to $65.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. Barclays cut their target price on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. TD Cowen raised their price target on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Benchmark reaffirmed a "buy" rating and set a $65.00 price target on shares of Exact Sciences in a research note on Monday, January 13th. Finally, Jefferies Financial Group raised their price target on shares of Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Exact Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $71.94.

Exact Sciences Price Performance

Exact Sciences stock traded down $0.68 during mid-day trading on Monday, reaching $47.82. The company had a trading volume of 2,339,154 shares, compared to its average volume of 2,321,709. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The company has a market cap of $8.88 billion, a P/E ratio of -8.59 and a beta of 1.24. The business has a fifty day simple moving average of $54.34 and a 200 day simple moving average of $59.87.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million.

Hedge Funds Weigh In On Exact Sciences

Large investors have recently modified their holdings of the company. Thompson Investment Management Inc. raised its position in Exact Sciences by 17.8% in the 4th quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock valued at $13,585,000 after buying an additional 36,505 shares during the last quarter. WCM Investment Management LLC raised its position in Exact Sciences by 1,153.2% in the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company's stock valued at $12,388,000 after buying an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. raised its position in Exact Sciences by 67.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company's stock valued at $1,994,000 after buying an additional 11,800 shares during the last quarter. Zacks Investment Management purchased a new stake in Exact Sciences in the 3rd quarter valued at $2,083,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Exact Sciences by 59.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company's stock valued at $22,868,000 after buying an additional 125,192 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.